Mineralys Therapeutics (NASDAQ:MLYS) Rating Reiterated by HC Wainwright
Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They presently have a $30.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 228.59% from the stock’s current price. Mineralys Therapeutics […]
More Stories
France on Fire: Who Is Behind the Riots, Who Benefits From the Chaos—and Could a Fallen Republic Put Nuclear Weapons at Risk?
By Stephen Zogopoulos, Founder & Chief Executive Officer, USNN World News France Is Not Simply Protesting. The Republic Is Facing...
US to Tap Petroleum Reserve for 400,000 Barrels in Exchange to Shore Up Louisiana Refinery
By Kimberly Hayek Federal officials authorized the release of up to 400,000 barrels of crude oil from the Strategic Petroleum...
Trump Calls On Data Center Developers to Pay Communities a Dividend
By Chris Summers President Donald Trump has suggested that companies building data centers in the United States should offer local...
Why America Has a Housing Shortage Alongside an Abundance of Empty Homes
By Autumn Spredemann Homes sit empty across the United States while potential owners and renters face affordability challenges and housing...
Riots, Rates, and Risks—The Economic Roots of France’s Unrest
By Andrew Moran Unrest has gripped France as nationwide protests over the rising cost of living have swept across the...
Employer Health Insurance Costs Rise as Workers Shoulder More of the Bill, Report Says
By Bill Pan Health care costs continued to rise for employers and workers this year, with employees paying more for...